Endocannabinoids produced upon action potential firing evoke a Cl− current via type-2 cannabinoid receptors in the medial prefrontal cortex

Pflugers Archiv European Journal of Physiology

Volumn 466, Issue 12, 2014, Pages 2257-2268

  den Boon, Femke S ^a   Chameau, Pascal ^a   Houthuijs, Kas ^a   Bolijn, Simone ^a   Mastrangelo, Nicolina ^b,c   Kruse, Chris G ^a   Maccarrone, Mauro ^c,d   Wadman, Wytse J ^a   Werkman, Taco R ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^d UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

2 AG; AEA; Ca2+ activated Cl current; In vitro brain slice preparation; Whole cell recording

Indexed keywords

2 ARACHIDONOYLGLYCEROL; CALCIUM ION; CANNABINOID 2 RECEPTOR; CHLORIDE; ENDOCANNABINOID; METHANANDAMIDE; VOLTAGE GATED CALCIUM CHANNEL; 2-ARACHIDONYLGLYCEROL; ACYLGLYCEROL; ARACHIDONIC ACID DERIVATIVE; CALCIUM CHANNEL N TYPE;

ACTION POTENTIAL; ANIMAL EXPERIMENT; ARTICLE; CALCIUM TRANSPORT; CHLORIDE CURRENT; CONTROLLED STUDY; MALE; MEDIAL PREFRONTAL CORTEX; MOUSE; NERVE EXCITABILITY; NONHUMAN; PHYSIOLOGICAL PROCESS; PREFRONTAL CORTEX; PYRAMIDAL NERVE CELL; SYNTHESIS; ANIMAL; C57BL MOUSE; CYTOLOGY; DRUG EFFECTS; GENETICS; METABOLISM; PHYSIOLOGY;

ACTION POTENTIALS; ANIMALS; ARACHIDONIC ACIDS; CALCIUM CHANNELS, N-TYPE; CHLORIDES; ENDOCANNABINOIDS; GLYCERIDES; MICE; MICE, INBRED C57BL; PREFRONTAL CORTEX; PYRAMIDAL CELLS; RECEPTOR, CANNABINOID, CB2;

EID: 84912026056     PISSN: 00316768     EISSN: 14322013     Source Type: Journal    
DOI: 10.1007/s00424-014-1502-6     Document Type: Article

References (52)

1. Akasu T, Nishimura T, Tokimasa T (1990) Calcium-dependent chloride current in neurones of the rabbit pelvic parasympathetic ganglia. J Physiol 422:303–320
2. Alger BE, Kim J (2011) Supply and demand for endocannabinoids. Trends Neurosci 34(6):304–315
3. Atwood BK, Straiker A, Mackie K (2012) CB(2) cannabinoid receptors inhibit synaptic transmission when expressed in cultured autaptic neurons. Neuropharmacology 63(4):514–523
4. Bandyopadhyay S, Hablitz JJ (2007) Dopaminergic modulation of local network activity in rat prefrontal cortex. J Neurophysiol 97(6):4120–4128
5. Brown SP, Brenowitz SD, Regehr WG (2003) Brief presynaptic bursts evoke synapse-specific retrograde inhibition mediated by endogenous cannabinoids. Nat Neurosci 6(10):1048–1057
6. Buczynski MW, Parsons LH (2010) Quantification of brain endocannabinoid levels: methods, interpretations and pitfalls. Br J Pharmacol 160(3):423–442
7. Castaneda JT, Harui A, Kiertscher SM, Roth JD, Roth MD (2013) Differential expression of intracellular and extracellular CB(2) cannabinoid receptor protein by human peripheral blood leukocytes. J NeuroImmune Pharmacol 8(1):323–332
8. Castillo PE, Younts TJ, Chavez AE, Hashimotodani Y (2012) Endocannabinoid signaling and synaptic function. Neuron 76(1):70–81
9. Chameau P, Inta D, Vitalis T, Monyer H, Wadman WJ, van Hooft JA (2009) The N-terminal region of reelin regulates postnatal dendritic maturation of cortical pyramidal neurons. Proc Natl Acad Sci U S A 106(17):7227–7232
10. Chavez AE, Chiu CQ, Castillo PE (2010) TRPV1 activation by endogenous anandamide triggers postsynaptic long-term depression in dentate gyrus. Nat Neurosci 13(12):1511–1518
11. Currie S, Rainbow RD, Ewart MA, Kitson S, Pliego EH, Kane KA, McCarron JG (2008) IP(3)R-mediated Ca(2+) release is modulated by anandamide in isolated cardiac nuclei. J Mol Cell Cardiol 45(6):804–811
12. den Boon FS, Chameau P, Schaafsma-Zhao Q, van Aken W, Bari M, Oddi S, Kruse CG, Maccarrone M, Wadman WJ, Werkman TR (2012) Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptors. Proc Natl Acad Sci U S A 109(9):3534–3539
13. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258(5090):1946–1949
14. Di Marzo V (2011) Endocannabinoid signaling in the brain: biosynthetic mechanisms in the limelight. Nat Neurosci 14(1):9–15
15. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S, Piomelli D (2002) Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A 99(16):10819–10824
16. Dinh TP, Kathuria S, Piomelli D (2004) RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. Mol Pharmacol 66(5):1260–1264
17. Fegley D, Gaetani S, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D (2005) Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 313(1):352–358
18. Fortin DA, Trettel J, Levine ES (2004) Brief trains of action potentials enhance pyramidal neuron excitability via endocannabinoid-mediated suppression of inhibition. J Neurophysiol 92(4):2105–2112
19. Fowler CJ (2013) Transport of endocannabinoids across the plasma membrane and within the cell. FEBS J 280(9):1895–1904
20. − channels—homing in on an elusive channel species. Prog Neurobiol 60(3):247–289
21. Gonsiorek W, Lunn C, Fan X, Narula S, Lundell D, Hipkin RW (2000) Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Mol Pharmacol 57(5):1045–1050
22. Hartzell C, Putzier I, Arreola J (2005) Calcium-activated chloride channels. Annu Rev Physiol 67:719–758
23. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11(2):563–583
24. Hogg RC, Wang Q, Large WA (1994) Effects of Cl channel blockers on Ca-activated chloride and potassium currents in smooth muscle cells from rabbit portal vein. Br J Pharmacol 111(4):1333–1341
25. Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R, Krey JF, Walker JM, Holmes PV, Crystal JD, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D (2005) An endocannabinoid mechanism for stress-induced analgesia. Nature 435(7045):1108–1112
26. Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M (2009) Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89(1):309–380
27. Katona I, Freund TF (2012) Multiple functions of endocannabinoid signaling in the brain. Annu Rev Neurosci 35:529–558
28. Kim J, Alger BE (2010) Reduction in endocannabinoid tone is a homeostatic mechanism for specific inhibitory synapses. Nat Neurosci 13(5):592–600
29. King AR, Duranti A, Tontini A, Rivara S, Rosengarth A, Clapper JR, Astarita G, Geaga JA, Luecke H, Mor M, Tarzia G, Piomelli D (2007) URB602 inhibits monoacylglycerol lipase and selectively blocks 2-arachidonoylglycerol degradation in intact brain slices. Chem Biol 14(12):1357–1365
30. Lafourcade M, Elezgarai I, Mato S, Bakiri Y, Grandes P, Manzoni OJ (2007) Molecular components and functions of the endocannabinoid system in mouse prefrontal cortex. PLoS ONE 2(8):e709
31. Lemtiri-Chlieh F, Levine ES (2007) Lack of depolarization-induced suppression of inhibition (DSI) in layer 2/3 interneurons that receive cannabinoid-sensitive inhibitory inputs. J Neurophysiol 98(5):2517–2524
32. Lerner TN, Kreitzer AC (2012) RGS4 is required for dopaminergic control of striatal LTD and susceptibility to parkinsonian motor deficits. Neuron 73(2):347–359
33. Leung LS, Peloquin P, Canning KJ (2008) Paired-pulse depression of excitatory postsynaptic current sinks in hippocampal CA1 in vivo. Hippocampus 18(10):1008–1020
34. Llano I, Leresche N, Marty A (1991) Calcium entry increases the sensitivity of cerebellar Purkinje cells to applied GABA and decreases inhibitory synaptic currents. Neuron 6(4):565–574
35. Lourenco J, Matias I, Marsicano G, Mulle C (2011) Pharmacological activation of kainate receptors drives endocannabinoid mobilization. J Neurosci 31(9):3243–3248
36. Luchicchi A, Pistis M (2012) Anandamide and 2-arachidonoylglycerol: pharmacological properties, functional features, and emerging specificities of the two major endocannabinoids. Mol Neurobiol 46(2):374–392
37. Lunn CA, Reich EP, Fine JS, Lavey B, Kozlowski JA, Hipkin RW, Lundell DJ, Bober L (2008) Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists. Br J Pharmacol 153(2):226–239
38. Maccarrone M, Dainese E, Oddi S (2010) Intracellular trafficking of anandamide: new concepts for signaling. Trends Biochem Sci 35(11):601–608
39. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR et al (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50(1):83–90
40. Onaivi ES, Ishiguro H, Gu S, Liu QR (2012) CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity. J Psychopharmacol 26(1):92–103
41. Pan B, Wang W, Long JZ, Sun D, Hillard CJ, Cravatt BF, Liu QS (2009) Blockade of 2-arachidonoylglycerol hydrolysis by selective monoacylglycerol lipase inhibitor 4-nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate (JZL184) Enhances retrograde endocannabinoid signaling. J Pharmacol Exp Ther 331(2):591–597
42. Pattij T, Wiskerke J, Schoffelmeer AN (2008) Cannabinoid modulation of executive functions. Eur J Pharmacol 585(2–3):458–463
43. Puente N, Cui Y, Lassalle O, Lafourcade M, Georges F, Venance L, Grandes P, Manzoni OJ (2011) Polymodal activation of the endocannabinoid system in the extended amygdala. Nat Neurosci 14(12):1542–1547
44. Shankar BB, Lavey BJ, Zhou G, Spitler JA, Tong L, Rizvi R, Yang DY, Wolin R, Kozlowski JA, Shih NY, Wu J, Hipkin RW, Gonsiorek W, Lunn CA (2005) Triaryl bis-sulfones as cannabinoid-2 receptor ligands: SAR studies. Bioorg Med Chem Lett 15(20):4417–4420
45. Stella N (2010) Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 58(9):1017–1030
46. Stella N, Schweitzer P, Piomelli D (1997) A second endogenous cannabinoid that modulates long-term potentiation. Nature 388(6644):773–778
47. Sugiura T (2009) Physiological roles of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Biofactors 35(1):88–97
48. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, Waku K (1995) 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215(1):89–97
49. Terranova JP, Michaud JC, Le Fur G, Soubrie P (1995) Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN55212-2: reversal by SR141716 A, a selective antagonist of CB1 cannabinoid receptors. Naunyn Schmiedeberg’s Arch Pharmacol 352(5):576–579
50. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, Stella N, Makriyannis A, Piomelli D, Davison JS, Marnett LJ, Di Marzo V, Pittman QJ, Patel KD, Sharkey KA (2005) Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310(5746):329–332
51. Wilson RI, Nicoll RA (2001) Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410(6828):588–592
52. Yoshino H, Miyamae T, Hansen G, Zambrowicz B, Flynn M, Pedicord D, Blat Y, Westphal RS, Zaczek R, Lewis DA, Gonzalez-Burgos G (2011) Postsynaptic diacylglycerol lipase mediates retrograde endocannabinoid suppression of inhibition in mouse prefrontal cortex. J Physiol 589(Pt 20):4857–4884